摘要
目的观察恩替卡韦联合苦参素治疗慢性乙型肝炎（乙肝）的临床疗效。方法选择慢性乙肝患者74例，随机分为两组。观察组40例采用恩替卡韦片0．5mg／d，口服，联合苦参素600mg／d，静脉注射治疗；对照组34例仅服用恩替卡韦片0．5mg／d。从治疗开始后1、3、6、9、12个月及随访期每半年复查血清HBeAg、Anti．HBe及丙氨酸氨荃转移酶（ALT）复常率。结果治疗开始后1、3、6、9、12个月及随访期每半年，观察组患者血清HBeAg及Anti-HBe转阴率分别为32．5％、45．0％、60．0％、60．0％、62．5％、62．5％和62．5％，均高于对照组的5．9％、5．9％、8．8％、11．8％、11．8％、11．8％和11．8％（x^2=5．46，12．83，25．22，21．68，24．79，24．79，24．79，均P〈0．05）。观察组ALT复常率分别为45．0％、67．5％、87．5％、90．0％、90．0％、90．0％和90．0％，均高于对照组的20．6％、32．4％、41．2％、50．0％、52．9％、52．9％和52．9％（x^2=4．60，10．36，20．67，14．47，12．08，12．08，12．08，均P〈0．05）。结论恩替卡韦联合苦参素用以治疗慢性乙肝具有协同抗病毒作用，治疗效果好、安全性高、治疗方案简单、值得临床推广使用。
Objective To observe the clinical effect of entecavir combined with oxymatrine in the treatment of patients with hepatitis B. Methods 74 patients with hepatitis B were randomly divided into two groups. The treatment group （40 eases） were given entecavir 0.5rag daily, oxymatine 600mg, intravenous daily. The control group （34 cases） were given entercavir 0.5mg daily. The HBeAg and Anti-HBe negative conversion rates, the HBV-DNA negative conversion rate and the ALT normalization rate after 1,3,6,9,12 months in treatment period and 6,12 months in follow-up period were observed. Results After 1,3,6,9,12 months in treatment period and 6,12 months in follow-up period,the HBeAg and Anti-HBe negative conversion rates of the treatment group was 32.5% ,45.0%, 60. 0% ,60. 0% ,62.5% ,62.5% and 62.5%, while that of the control group was 5.9% ,5.9% ,8.8%, 11. 8%, 11.8% , 11.8% and 11.8%, there was significant difference between them （ X2 = 5.46,12.83,25.22,21.68,24.79, 24.79,24.79 ,all P 〈 0.05 ）. The ALT normalization rate of the treatment groups was 45.0%, 67.5%, 87.5%, 90.0% ,90.0% ,90.0% and 90.0% ,while that of the control group was 20.6% ,32.4% ,41.2% ,50.0% ,52.9%, 52.9% and 52.9%, there was significantly difference between them （ X2 = 4.60, 10.36,20.67, 14.47, 12.08, 12.08,12.08, all P 〈0. 05 ）. Conclusion Entecavir combined with oxymatrine in the treatment of patients with hepatitis B had a synergistic antiviral effect, high security and simple treatment. It was worthy to promote.
出处
《中国基层医药》
CAS
2012年第4期531-532,共2页
Chinese Journal of Primary Medicine and Pharmacy
